Molecular imaging of DNA synthesis: Diagnosis of cancer using a new PET tracer

Molecular imaging of DNA synthesis: Diagnosis of cancer using a new PET tracer - 4&#39;-[methyl-11C]thiotymidine(4DST)PET for cancer diagnosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005850

Enrollment

300

Registered

2011-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Multiple myeloma Esophageal cancer Head and neck caner

Interventions

4DSTPET and FDGPET in a same patient will be compared to the pathology or to the clinical golden standards.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient who is pathologically diagnosed as malignancy. 2.Age: >20 years. 3. Capability to have PET scan. 4. Completed the written informed consent

Exclusion criteria

Exclusion criteria: 1. Unable to have signed informed consent. 2.Patient with severe underlying disease having risk of liver dysfunction, renal dysfunction and any metabolic damage. 3. Just after surgery and/or trauma 4. Uncontrollable diabetics 5. Those who are determined as not appropriate for the study by physician in chief.

Design outcomes

Primary

Measure	Time frame
As a surrogate marker of tumor proliferation and of therapeutic response, 4DST-PET could be superior than FDG-PET.	—

Countries

Japan

Contacts

Public ContactRyogo Minamimoto

National Center for Global Health and Medicine Department of Radiology, Division of Nuclear Medicine

rikensa@lily.ocn.ne.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026